This week (April 28 to May 2), three companies, including d'Alba Global, which is considered a promising player in the K-beauty sector, will conduct demand forecasting in the IPO market. The biotech company Organoid Science, which is developing regenerative therapies, plans to offer a public subscription for its KOSDAQ listing.
According to the financial investment industry on the 27th, d'Alba Global will conduct demand forecasting for institutional investors from the 28th to the 7th of next month. The supervising underwriter for the listing is Mirae Asset Securities, and the proposed public offering price range per share has been set between 54,500 won and 66,300 won.
d'Alba Global is considered a promising player in K-beauty, succeeding the beauty tech company APR. Its flagship product, a mist serum commonly known as the 'flight attendant mist,' generated sales exceeding 300 billion won last year, with an operating profit amounting to 59.8 billion won.
Additionally, the biotech company IntoCell and OLED component manufacturer FineOne will also start demand forecasting for institutional investors from the 29th. IntoCell is noted for being founded by Park Tae-kyo, who is a co-founder of LigaChem Biosciences.
Moreover, Organoid Science will accept subscriptions for its IPO from general investors. Organoid Science specializes in 'organoid' technology that cultivates stem cells to create tissues similar to human organs.
Meanwhile, this week, new stocks are also set to debut on the KOSDAQ market. The electronic beam inspection equipment specialist SEC will be listed on the KOSDAQ on the 28th. SEC previously raised more than 2 trillion won in deposits from general investor subscriptions.